Drug intelligence / Profile preview

donepezil + duloxetine

Development stage
Phase 4
Lead developer
Eisai
Modality
Small Molecules
Administration
Oral
01

Overview

The combination of donepezil and duloxetine represents a drug pairing that has been studied for potential therapeutic benefits, particularly in the treatment of neuropathic pain and potentially in cognitive conditions. Donepezil and duloxetine is a drug combination that works through complementary mechanisms of action. Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain, primarily used for Alzheimer's disease and other forms of dementia[3][6]. Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI) that increases the availability of these neurotransmitters in the central nervous system, commonly used for depression, anxiety disorders, and neuropathic pain[8][9]. When combined, these medications may offer synergistic effects, particularly in the treatment of neuropathic pain. Research suggests that this combination, especially when used with gabapentin, can produce enhanced analgesic effects through the modulation of the bulbospinal-spinal noradrenergic-cholinergic pathway[4][5]. The combination has been investigated in clinical trials for conditions such as diabetic neuropathic pain and failed low back syndrome.

02

Targets

AcetylcholinesteraseButyrylcholinesteraseNET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on donepezil + duloxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on donepezil + duloxetine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call